Aurobindo Pharma Secures USFDA Approval for First Complex MDI Inhaler
Aurobindo Pharma Ltd 路 Press Release 路 15 Sept 2026, 6:40 pm
Aurobindo Pharma Secures USFDA Approval for First Complex MDI Inhaler Aurobindo Pharma received USFDA final approval on 15th Sep'26 for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg), a generic equivalent of Teva鈥檚 QVAR. Marking Aurobindo鈥檚 first metered-dose inhaler product, it will be manufactured at subsidiary Aurolife Pharma's North Carolina facility with launches slated for upcoming quarters. According to IQVIA, the relevant US market was valued at US$301 million for the 12 months ended Jul'26. This expands Aurobindo's cumulative USFDA ANDA portfolio to 596 approvals (571 final, 25 tentative).
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
